文献速递前列腺癌

唑来膦酸联合恩扎卢胺及雄激素剥夺治疗转移性激素敏感性前列腺癌:随机II期BONENZA试验

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-05-03

BONENZA是一项随机II期多中心试验,纳入126例有骨转移的mHSPC患者,1:1随机接受恩扎卢胺单药或联合唑来膦酸,主要终点为WB-DW-MRI评估的骨转移灶总体缓解率。中位随访31.9个月,两组ORR无差异(69.8% vs 对照组,OR 1.00,95%CI 0.47-2.15,p>0.9),PFS和OS亦无获益。

要点

  • 唑来膦酸未提高恩扎卢胺联合ADT的骨转移缓解率。
  • WB-DW-MRI是评估前列腺癌骨转移系统治疗反应可靠技术。
  • 联合唑来膦酸未改善PFS或OS。

核心结论

  • 在mHSPC患者中,唑来膦酸未改善恩扎卢胺联合ADT的骨缓解率。
  • WB-DW-MRI是评估前列腺癌骨转移对系统治疗反应的可靠技术。

研究设计与样本

  • BONENZA为随机II期多中心临床试验,2018年2月至2021年6月入组126例骨扫描证实骨转移的mHSPC患者。
  • 患者1:1随机接受恩扎卢胺160 mg口服每日一次单药(E组)或联合唑来膦酸4 mg静脉每4周一次(EZ组)。
  • 主要终点为WB-DW-MRI评估的骨转移总体缓解率(ORR),次要终点包括传统影像ORR、PFS和OS。

主要发现

  • 中位随访31.9个月,意向性分析显示两组ORR相似:69.8%(95%CI 57.5-79.9%),OR 1.00(95%CI 0.47-2.15;p>0.9)。
  • EZ组对比E组PFS无优势:HR 0.77(95%CI 0.44-1.37;p=0.4)。
  • EZ组对比E组OS无优势:HR 1.09(95%CI 0.54-2.2;p=0.8)。

临床怎么用

  • 对于mHSPC骨转移患者,不应在恩扎卢胺联合ADT基础上常规加用唑来膦酸以期提高骨缓解率。
  • WB-DW-MRI可用于评估前列腺癌骨转移对系统治疗的反应。

局限性

  • WB-DW-MRI无法评估17例患者的疾病反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zoledronic acid (ZA) in combination with androgen deprivation therapy (ADT) has never proved additional activity in patients with advanced prostate cancer. However, conventional imaging is poorly reliable in monitoring disease response of metastatic bone lesions. METHODS: BonEnza is a randomized phase II multicenter clinical trial designed to compare activity of ADT plus Enzalutamide (E) plus/minus ZA in term of bone response rate by Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (WB-DW-MRI). From February 2018 to June 2021, 126 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and bone metastasis at bone scan were enrolled. Patients were randomized in a 1:1 to receive E 160 mg OD orally alone (E arm) or in combination with ZA 4 mg intravenously every 4 weeks (EZ arm). Primary endpoint of the study was overall response rate (ORR) in bone metastases, secondary endpoints were ORR with conventional imaging, progression free survival (PFS) and overall survival (OS). A logistic model was used to evaluate the association between treatment arm and ORR. RESULTS: After a median follow-up of 31.9 months, according to an intent to treat analysis, the ORR was superimposable in both arms: 69.8% (95% Confidence Interval [CI]: 57.5-79.9%), Odds Ratio: 1.00 (95%CI 0.47-2.15; p > 0.9). No advantage in favor of EZ arm over E arm emerged either in terms of PFS (Hazard Ratio [HR] 0.77, 95%CI 0.44-1.37; p = 0.4) or OS (HR 1.09; 95%CI 0.54-2.2; p = 0.8). A main limitation of this study was the inability of WB-DW-MRI to evaluate disease response in 17 patients. CONCLUSIONS: ZA did not improve bone response rate to E plus ADT in mHSPC patients. WB-DW-MRI is a reliable technique to evaluate the response of prostate cancer bone metastases to systemic therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dalla Volta A, Valcamonico F, Zivi A, et al. Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial. Prostate Cancer Prostatic Dis. 2025. PMID: 40319177. doi:10.1038/s41391-025-00975-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。